Mary Washington Healthcare Introduces Accurate, Non-Invasive, Painless Option to Aid in Liver Management

Fredericksburg, VA - (April 27, 2018) - Mary Washington Healthcare (MWHC) is pleased to announce it now offers patients non-invasive, painless liver assessments with FibroScan®, the first device to be FDA-cleared as an aid to management of patients with liver disease.

An examination with FibroScan®, also called transient elastography, is a non-invasive way to measure the stiffness of the patient’s liver. FibroScan® works by emitting a small pulse of energy, which may feel as a slight vibration on your skin. FibroScan calculates the speed of this energy to give your healthcare provider an immediate measure of the stiffness of your liver. This stiffness measure can be an important part of understanding your overall liver health. FibroScan® examinations are covered by most insurance plans.

“We are pleased to offer this important advance in liver management to our patients. Its consistent results enable us to make the most informed treatment decisions while providing the quick, painless experience patients want,” said Dr. Peter Wong, MD, FACP, FACG, MWHC Endoscopy Chairman and practicing gastroenterologist with Gastroenterology Associates of Fredericksburg,

Mary Washington Healthcare is a fully integrated, regional medical system that provides inpatient and outpatient care through more than 40 facilities and services including Mary Washington Hospital, a 451-bed regional medical center, and Stafford Hospital, a 100-bed community hospital. Mary Washington Healthcare is a not-for-profit health system with a longstanding commitment to provide care regardless of ability to pay. For more information about our services and facilities, please visit Mary Washington Healthcare website.